Raj Reddy
Chief Executive Officer Canary Cure
Seminars
This intensive workshop will delve into the cutting-edge integration of genetic and
proteomic profiling to overcome the “one-size-fits-all” limitation of current obesity therapeutics. By leveraging high-resolution molecular data, participants will learn to transition from broad-spectrum weight loss approaches to precision-led development strategies that identify high-responders and mitigate non-response early in the pipeline. The session will focus on utilizing multi-omic insights to enhance trial predictability, minimize late-stage attrition, and deliver personalized cardiometabolic solutions with proven clinical superiority.
This session will cover:
- Implementing multi-omic patient stratification to move beyond BMI-based enrollment, using polygenic risk scores (PRS) and proteomic signatures to identify sub-populations with the highest probability of therapeutic response
- Decoding genetic drivers of non-response by analyzing the molecular heterogeneity of obesity (such as MC4R or INHBE variants) to predict why certain cohorts remain refractory to standard GLP-1/GIP therapies
- Utilizing proteomic biomarkers for early efficacy signals to identify real-time changes in metabolic health and adipose tissue distribution, providing objective proof-of-concept data long before significant weight loss is visible on the scale
- Integrating precision medicine into trial design through the use of biomarkerenriched protocols and adaptive “basket” trials that dynamically group patients based on their specific genetic metabolic drivers
- Establishing AI-driven predictive models that link large-scale genomic data to clinical outcomes, allowing development teams to optimize drug-target pairing and justify investment in personalized “next-generation” obesity assets
- Case study with Canary Cure: Integrating large-scale human genomic data and AI to identify the specific cross-talk between the CB1R and ZFP423 genes to deliver a dual gene-silencing therapy that precisely triggers the “browning” of white fat cells within 72 hours, ultimately providing an early proteomic proof-of-concept that identifies high-responders and secures a 25% increase in lean muscle mass for superior body composition results
- Prioritizing the resolution of co-morbidities such as MASH, CKD, and heart failure to move beyond BMI reduction as the sole metric of clinical success, establishing obesity drugs as essential “foundation therapies” for lifelong cardiometabolic protection
- Implementing evidence-based “step-down” protocols, transitioning patients from high-dose injectable peptides to low-dose oral small molecules or RNA-based silencers to suppress the biological “rebound effect” after reaching goal weight for durable weight stability and higher long-term therapy persistence
- Integrating longitudinal data on physical function, hospitalization rates, and employment status to quantify the total economic value of long-term obesity treatment, providing a robust scientific justification for expanded reimbursement and universal patient access across diverse socioeconomic populations
• Introduction to the Modular Next Gen Hyper15™ Delivery Platform, the first technology capable of bypassing the endosome to successfully deliver dual siRNA payloads directly to adipose tissue. This breakthrough enables precise genetic silencing within the fat cell itself, treating the tissue as a metabolic organ rather than just a storage depot.
Differentiating CCT-217 from standard-of-care incretins by moving “Beyond Appetite.” We present data showing how silencing adipose-specific genes at their mitochondrial receptors unlocks thermogenic energy expenditure and lipolysis, driving weight loss through metabolic upregulation rather than caloric restriction/starvation physiology.
A deep dive into the compositional and commercial advantage of CCT-217. We demonstrate how CCT-217 delivers Selective Fat Mass reduction and Muscle Enhancement—avoiding the sarcopenic trap of GLP-1s—while offering an Ultra-Long Duration dosing profile (6+ months) that redefines treatment adherence
